 |
| Modules | |
| Google | |
|
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS. | |
| Languages | |
|
Select Interface Language:
| |
| Who''s Online | |
There are currently, 178 guest(s) and 64 member(s) that are online.
You are Anonymous user. You can register for free by clicking here | |
| Next Step | |
| Donations | |
|
To remain unbiased, This is MS does not accept corporate sponsorships. Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you! | |
| |
 | All comments and suggestions about this web site are very welcome and a valuable source of information for us. Thanks! |
|
|
| |
| Login | |
|
Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. | |
| Survey | |
| Big Story of Today | |
|
There isn't a Biggest Story for Today, yet. | |
| Old Articles | |
| Monday, June 05 | | · | Tysabri Cleared to Return to Market |
| · | Hope and Heartbreak: The Path of Tysabri as a Treatment for Multiple Sclerosis |
| Thursday, June 01 | | · | Biogen Buys Another Promising MS Drug (BG-12) |
| Friday, May 26 | | · | Early Treatment Favoured for MS |
| Thursday, May 25 | | · | Elan Says Tysabri on Track, Considers Price Hike |
| · | Monthly IV Steroids Could Prevent Relapses |
| Tuesday, May 23 | | · | Possible Method of Action for Copaxone Discovered |
| Monday, May 22 | | · | Keppra (Levetiracetam) shows Promise Against Tremor |
| Friday, May 19 | | · | First Formal Low Dose Naltrexone Study Results to be Presented |
| Wednesday, May 17 | | · | Possible Shift in Thinking about how Multiple Sclerosis Develops |
| Tuesday, May 16 | | · | BioMS expands MBP8298 trial to RRMS patients |
| Thursday, March 30 | | · | Daclizumab Method of Action Surprises Researchers |
| Wednesday, March 22 | | · | FDA Extends Tysabri Review by up to 90 Days |
| Wednesday, March 08 | | · | US FDA PANEL UNANIMOUS: TYSABRI SHOULD RETURN |
| Tuesday, March 07 | | · | First Day of Tysabri AC Meeting Over |
| · | In Progress: Tysabri FDA Advisory Panel Review Meeting |
| Wednesday, March 01 | | · | New Tysabri Results Published in New England Journal of Medicine |
| Tuesday, February 28 | | · | Interesting new Research Abstracts on Tsyabri (Natalizumab) |
| Wednesday, February 15 | | · | Tysabri Cleared for Clinical Trial Use |
| Monday, February 06 | | · | MN-166 Enters Phase II trials in US |
| Tuesday, January 24 | | · | Tysabri to Receive FDA Verdict by end of March |
| Friday, November 18 | | · | FDA grants Priority Review to Tysabri Supplemental Application |
| Monday, November 07 | | · | Component of Turkey (Tryptophan) Promising in MS |
| Monday, October 17 | | · | Tysabri Crohn''s and RA Safety Review Complete; No New PML |
| Monday, October 03 | | · | Novartis Oral Therapy FTY-720 Shows Phase II Success |
| Monday, September 26 | | · | Tysabri Supplemental Application Submitted to FDA |
| Tuesday, September 20 | | · | Elan and Biogen Plan Re-Launch of Tysabri |
| · | Stem Cells Repair Cord Damage; Produce Myelin |
| · | Campath Trials Temporarily Halted; Shows Promise |
| · | Long-Term Antibiotic Use Raises Cold and Flu Risk |
Older Articles
| |
| Latest Forum Posts | |
| Information | |
|
This site is privately funded by individuals interested in fighting multiple sclerosis.
There are no corporate grants, medical center affiliations, or overbearing advertisements, providing a truly independent online community for MS.
Note that all medical decisions should be made with the consent of your doctor. | |
|
|
